Clinical Trials Logo
  1. Home
  2. Neurotrophic Keratitis
  3. NCT04485546

Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis — DEFENDO  

Neurotrophic Keratitis Clinical Trial

Official title:
An 8-week, Multicenter, Open Label, Prospective Study With 24 Weeks of Follow-up to Evaluate Safety and Efficacy of OXERVATE™ 0.002% (20 mcg/mL) Cenegermin-bkbj Ophthalmic Solution in Patients With Stage 1 Neurotrophic Keratitis (NK)

Clinical Trial Summary

This study is to evaluate the safety and efficacy of OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in patients with Stage 1 neurotrophic keratitis (NK).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04485546
Study type Interventional
Source Dompé Farmaceutici S.p.A
Contact
Status Completed
Phase Phase 4
Start date September 9, 2020
Completion date March 30, 2022
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05927428 - Assessment of the Safety and Efficacy of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis Phase 2
Completed NCT04552730 - Nerve Growth Factor for the Treatment of Cornea Disease
Completed NCT04276558 - REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients Phase 2
Recruiting NCT04573647 - OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate
Completed NCT04820010 - Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3
Recruiting NCT04627571 - Corneal Nerves After Treatment With Cenegermin
Enrolling by invitation NCT05758753 - QST for Corneal Nerve Function N/A
Terminated NCT05809245 - Corneal Neurotization as a Treatment for Neurotrophic Keratopathy N/A
Withdrawn NCT05321251 - Topical Insulin Drops for the Treatment of Neurotrophic Keratopathy. Phase 2/Phase 3
Terminated NCT03037450 - Miniinvasive Corneal Neurotization. A Pilot Study. N/A
Not yet recruiting NCT06364657 - Differences in Corneal Structure and Function in Patients With Sjogrens vs. Non-Sjogrens Dry Eye
Recruiting NCT05566717 - An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity
Not yet recruiting NCT02707120 - Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) Eye-drops in the Treatment of Neurotrophic Keratitis Phase 4
Completed NCT01756456 - Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis. Phase 1/Phase 2
Completed NCT02227147 - Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK Phase 2
Recruiting NCT05552261 - DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
Recruiting NCT04909450 - Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects Phase 1/Phase 2
Active, not recruiting NCT06411145 - Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis Phase 4